Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Latest News

Ahsan Arozullah, MD, MPH
Enzalutamide Plus Leuprolide Improves MFS in Nonmetastatic Castration-Sensitive Prostate Cancer

March 17th 2023

Enzalutamide plus leuprolide demonstrated a statistically significant and clinically meaningful improvement in metastasis-free survival compared with placebo plus leuprolide in patients with nonmetastatic castration-sensitive prostate cancer with a high-risk of biochemical recurrence.

FDA Expands Indication of Illuccix Companion Diagnostic for PSMA-Directed Radioligand Therapy in Metastatic Prostate Cancer

March 16th 2023

BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors
BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors

March 15th 2023

Ahsan Arozullah, MD, MPH
China ARCHES Study Meets Primary, Secondary End Points in Metastatic Prostate Cancer

March 14th 2023

Benjamin Garmezy, MD
Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023

Video Series
Video Interviews

More News